DNDI-6148( —— )

Catalog No. M35150 CAS No. 2243909-59-1

DNDI-6148 has anti-experimental cutaneous leishmaniasis activity and can be used to study visceral leishmaniasis by inhibiting Leishmania protozoa cleavage and polyadenylation-specific factor (CPSF3) endonuclease.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	445	Get Quote
5MG	686	Get Quote
10MG	938	Get Quote
25MG	1398	Get Quote
50MG	1822	Get Quote
100MG	2484	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

DNDI-6148
Note

Research use only, not for human use.
Brief Description

DNDI-6148 has anti-experimental cutaneous leishmaniasis activity and can be used to study visceral leishmaniasis by inhibiting Leishmania protozoa cleavage and polyadenylation-specific factor (CPSF3) endonuclease.
Description

DNDI-6148 is a novel preclinical candidate for the research of visceral leishmaniasis.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Microbiology/Virology
Target

Parasite
Recptor

Parasite
Research Area

——
Indication

——

Chemical Information

CAS Number

2243909-59-1
Formula Weight

335.13
Molecular Formula

C16H14BN5O3
Purity

>98% (HPLC)
Solubility

——
SMILES

O=C(NC1=CC=C2C(=C1)B(O)OC2)C=3N=NN(C4=NC=CC=C4)C3C
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Mowbray CE, et al. DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. J Med Chem. 2021 Nov 11;64(21):16159-16176. ?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks